Faricimab
Based on 1 Customer Validation
Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO).
For research use only. We do not sell to patients.
- Purity : 99.00%
- CAS No.: 1607793-29-2
- Molecular Weight:146.16 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
All VEGFR Isoforms
More
Biological Activity
Description
Isotype
IgG1-kappa-lambda with half-IG VL-CH1/VH-CK crossover
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
ANG2 & VEGFA
In Vitro
Faricimab (2000 ng/mL, 37 days) to pharmaceutical compounding and storage for up to 37 days has no impairment on its bispecific antigen-binding properties and has a structural integrity of the IgG1 Fc fragment[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Faricimab (3 μg/μL, intravitreal injections, a single dose for 48 h) prevents ischemia/reperfusion (I/R) injury-induced retinal permeability and cell death in retinal I/R injury mouse model[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Retinal I/R injury mouse model[4]
-
Dosage:3 μg/μL
-
Administration:intravitreal injections, a single dose for 48 h
-
Result:Significantly reduced retinal vascular permeability (by 64%) and cell death compared with IgG control-treated mice.
-
Animal Model:JR5558 mice[4]
-
Dosage:10 mg/kg
-
Administration:i.p., twice interval 1 week for 1 or 5 weeks
-
Result:Might promote vascular stability by inhibiting neovascularization and subsequent neovascular leakage and decreased immune cell accumulation associated with sCNV lesions in JR5558 mice.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
IgG1-kappa-lambda with half-IG VL-CH1/VH-CK crossover
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Faricimab can bind VEGF165 Protein, Human.The EC50 for this effect is 3.418 ng/mL. -
Immobilized Faricimab can bind Human Angiopoietin-2/ANGPT2 Protein (His Tag).The EC50 for this effect is 4.10 ng/mL. -
Flow cytometric analysis of 1X106 HeLa cells with Faricimab (HY-P99116, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control.
Chemical Information
-
CAS No. 1607793-29-2
-
Appearance Liquid
-
Molecular Weight 146.16 kDa
-
Color Colorless to light yellow
-
SMILES
[Faricimab]
-
Synonyms
RG7716; RO-6867461
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (264 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Sahni J, et al. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. Ophthalmology. 2019 Aug;126(8):1155-1170. [Content Brief]
[2]. Nicolò M, et al. Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases[J]. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200. [Content Brief]
[3]. Penha FM, et al. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME[J]. Int J Retina Vitreous. 2024 Jan 17;10(1):5. [Content Brief]
[4]. Canonica J, et al. Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia/reperfusion[J]. Front Cell Neurosci. 2023 Jun 12;17:1192464. [Content Brief]
[5]. Jørstad ØK, et al. Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding properties[J]. Int J Retina Vitreous. 2023 Nov 7;9(1):65. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)